Abstract
Background The unprecedented demand and consequent global shortage of N95 respirators during the COVID-19 pandemic have left frontline workers vulnerable to infection. To expand the supply, we validated a rapidly applicable low-cost decontamination protocol in compliance with US-regulatory guidelines to enable the safe reuse of personalized, disposable N95-respirators.
Methods Four common models of N95-respirators were disinfected for 60 minutes at 70°C either at 0% or 50% relative humidity (RH). Effective inactivation of SARS-CoV-2 and E. coli was evaluated in inoculated masks. The N95 filter integrity was examined with scanning electron microscopy. The protective function of disinfected N95 respirators was tested against US NIOSH standards for particle filtration efficiency, breathing resistance and respirator fit.
Results A single heat treatment inactivated SARS-CoV-2 (undetectable, detection limit: 100 TCID50/ml) and E. coli (0 colonies at 50%RH) in all four respirator models. Even N95-respirators that underwent ten dry heat, or up to five 50%RH-controlled decontamination cycles maintained their integrity and met US-governmental criteria for approval regarding fit (10x dry heat: 194.48±15.5; 99%CI: 185.5 to 203.5; 5x at 50%RH: 198.2±6.3; 99%CI: 189.4 to 207; n=23 each, pass value ≥ 100,), breathing resistance (10x dry heat: 68.0±8.4 Pa, 99%CI: 61.8 to 74.1, n=16; 5x at 50%RH: 78.5±19.7 Pa, 99%CI: 21 to 135.9, n=4, pass value ≤ 343.23Pa), and filtration levels (10x dry heat: 97.6±1.1%, 99%CI: 96.8 to 98.4; n=16; 5x at 50%RH: 97.18±0.49, 99%CI: 95.7 to 98.6, n=4, pass value ≥ 95 %).
Interpretation This rapid process enables large-scale decontamination of existing N95-respirators using commonly sourced equipment during the COVID-19 pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding was obtained from the Health and Medical Research Fund, Hong Kong and National Institute of Allergy and Infectious Diseases, National Institutes of Health. The funder had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional approvals were provided. Ethical approval was not required for this research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets are available from the corresponding author on reasonable request.
